Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pavmed Inc (PAVM)

Pavmed Inc (PAVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference

/PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device,...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
PAVmed Provides Business Update and Second Quarter Financial Results

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

LUCD : 0.7635 (-2.12%)
PAVM : 0.7200 (+1.41%)
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023

/PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device,...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)
PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the...

PAVM : 0.7200 (+1.41%)
LUCD : 0.7635 (-2.12%)

Barchart Exclusives

The Spring Doldrums in The Gold Market May Be Changing Soon
Over the past five years, data shows distinct patterns in the seasonality of gold prices. September has consistently been weak, with prices often closing lower than they opened, suggesting a decrease in market confidence or a shift in investment focus. In contrast, due to increased buying, July has shown a higher probability of gold prices closing above their opening mark. Are the Spring doldrums in gold prices ready to change to higher prices? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar